Amgen advances obesity pipeline focus, shares hold near recent highs

Amgen leans on its early-stage obesity drug portfolio and wider pipeline strength as analysts highlight the biotech’s role in the fast-growing weight-loss market, with the NASDAQ-listed shares trading close to year-to-date highs.

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-29, 10:16.

Amgen Inc. (US0311621009) continues to attract attention in the large-cap biotech segment. The NASDAQ-listed company is being discussed for its pipeline, notably in obesity and inflammation, as recent analyst commentary points to long-term growth potential in these areas.Finanzen100 overview on Amgen

What recent reports highlight

Recent coverage has drawn attention to Amgen’s pipeline strength and early-stage obesity drug candidates, positioning the company alongside major weight-loss players such as Eli Lilly and Novo Nordisk.Finanzen100 summary citing analyst views Piper Sandler and Morgan Stanley have both commented on Amgen, emphasizing obesity drug potential as one of the longer-term drivers for the business.GuruFocus note on Amgen coverage

Alongside obesity prospects, Amgen’s broader pipeline in oncology, inflammation and rare disease remains central to analyst assessments. The company’s diversification across therapeutic areas is often cited as a factor supporting its valuation compared with more narrowly focused peers.MarketBeat news aggregation on Amgen

Position in the S&P 500 healthcare cohort

Amgen is a member of the S&P 500 and ranks among the largest global biopharmaceutical companies by market capitalization, with a value around 193 billion US dollars based on recent NASDAQ data.TradingKey snapshot on AMGN The shares have gained roughly 9 to 10 percent since the start of the year, moving from approximately 327 dollars to the high 350-dollar range as of late June 2026.MarketBeat performance data for AMGN

Analyst consensus compiled by TradingKey assigns Amgen an overall "signal_hold" rating, with a reported average price target around 361.78 dollars per share.TradingKey analyst-rating overview This implies only a modest upside from current levels, underscoring that much of the expected value from the pipeline, including obesity candidates, is already partly reflected in the share price.

The product engine behind Amgen

Amgen generates revenue from a broad portfolio of biologic medicines, including established products such as Enbrel for inflammatory diseases and Prolia for osteoporosis, as well as newer therapies in oncology and bone health.Amgen overview of key medicines The company also invests heavily in early-stage programs, including obesity drug candidates that could complement or compete with existing GLP-1-based treatments in the coming years.

Where the shares trade today

Amgen shares (US0311621009) last closed on NASDAQ at 358.33 US dollars on 2026-06-26, based on TradingKey data, with a market capitalization around 193.07 billion US dollars.TradingKey price and market-cap data

Key data on the Amgen shares

• Company: Amgen Inc.
• ISIN: US0311621009
• WKN: 867900
• Ticker: AMGN
• Trading venue: NASDAQ
• Price (as of 2026-06-26, 16:00): 358.33 USD
• Market cap: 193.07 billion USD (as of 2026-06-26)
• Sector / industry: Health Care / Biotechnology
• Index membership: S&P 500
• Next earnings date: not officially scheduled

This article is for informational purposes only and does not constitute investment advice, investment recommendation or an offer or solicitation to buy or sell any financial instrument. Investors should conduct their own research or consult a qualified financial advisor before making investment decisions.